New study probes why diabetes patients develop fatty liver

NCT ID NCT07246421

Recruiting now Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the hormone glucagon works in people with type 2 diabetes, with or without fatty liver disease. Researchers will give participants low and high doses of glucagon and use scans and blood tests to measure how the liver and heart respond. The goal is to understand if glucagon resistance contributes to liver fat buildup and heart problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Glucagon infusion
What this could lead to: If successful, this study could reveal why some people with type 2 diabetes develop fatty liver and heart problems, pointing toward new treatment targets.
What could go wrong: This is a small, early-stage observational study with only 24 participants, so results may not apply to everyone. It is designed to gather knowledge, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC ASSOCIATED FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC ASSOCIATED FATTY LIVER DISEASE TYPE 2 DIABETES (T2DM)

Contacts and locations

Locations

Aarhus University Hospital
RECRUITING

Aarhus, 8000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.